Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04652973 · ClinicalTrials.gov registry record
Evaluation of Atherosclerotic Plaques in Abdominal CT Studies
A clinical trial of Prostatic Neoplasms, sponsored by National Institutes of Health Clinical Center (CC).
- Active
- Registry status
- 118
- Enrollment target
- 1
- Study location
NCT04652973: Active study of Prostatic Neoplasms, sponsored by National Institutes of Health Clinical Center (CC).
NCT04652973 is a study of Prostatic Neoplasms that is active but no longer recruiting, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 118 participants, below the 512-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04652973, a study of Prostatic Neoplasms, is active but no longer recruiting, sponsored by National Institutes of Health Clinical Center (CC).
- ACTIVE NOT RECRUITING
- Registry status
- 118 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Fat and calcium can build up as plaque in artery walls. The Agatston score measures plaque using computed tomography (CT) that does not use an injected contrast agent. Plaque in the arteries of the pelvis and abdomen is linked to cardiovascular disease (CVD) risk factors. It also may affect cancer. But abdominal CTs use a contrast agent (CECT). Therefore, the Agatston score cannot be used. Researchers want to find a way to measure plaque in CECTs. This will help them use abdominal CTs to measure plaque without extra radiation. Objective: To measure atherosclerotic plaques on CECT in a group of males. Eligibility: Men ages 30-90 with prostate cancer (proven with biopsies) who have abdomen CT studies in the PACS (picture archiving system) in the Clinical Center. Also, men or women of all ages who have multiphase abdomen and pelvic CT studies that are in the PACS. Design: This study will use data gathered since 1/1/2013. Data will also be taken from protocol 03-CC-0128 and clinical trials 15-C-0124, 16-C-0048, 14-C-0112, and 04-C-0274. Participants from these studies have allowed their samples to be used in the future. Participants will be found via keyword searches on NIH databases. Their CT and MRI scans will be used. Data such as age, race, disease, and treatment will be used. Results of other tests may be used. The plaque in participants abdomen and iliac arteries will be measured. It will be compared with biomarkers related to CVD and prostate cancer, such as weight, age, and race. This study will take place at one site. Data will be stored on secure computers. Printouts will be kept in locked rooms.
Primary Outcome
Measure atherosclerotic plaques on contrast-enhanced computed tomography (CECT)
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2020-11-19 |
| Est. Completion | 2030-08-30 |
What the registry record for NCT04652973 still lists
NCT04652973 is an observational study that tracks outcomes without assigning an intervention. The registered 118 participants enrollment target is mid-sized for trials with a published cap, below the 512-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Prostatic Neoplasms appearing as the primary indexed condition, and to 0 interventions.
NCT04652973 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT04652973 about?
NCT04652973 is a clinical study titled "Evaluation of Atherosclerotic Plaques in Abdominal CT Studies". Background: Fat and calcium can build up as plaque in artery walls. The Agatston score measures plaque using computed tomography (CT) that does not use an injected contrast agent. Plaque in the arteries of the pelvis and abdomen is linked to cardiovascular disease (CVD) risk factors. It also may af...
What is the current status of trial NCT04652973?
This trial is currently active not recruiting. The enrollment target is 118 participants. The study started on 2020-11-19. Estimated completion is 2030-08-30.
What conditions does trial NCT04652973 study?
This clinical trial studies the following conditions: Prostatic Neoplasms.
Who is sponsoring clinical trial NCT04652973?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04652973 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04652973's enrollment target sits among peer trials
118 38th of 65 higher than 28 of 65 other Prostatic Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostatic Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prostate Active Surveillance Study
RECRUITING
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
-
Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture
RECRUITING · NA
-
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
RECRUITING · Phase 1
-
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
RECRUITING
-
Men at High Genetic Risk for Prostate Cancer
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03821623 · 118 participants · Phase 2
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
- NCT04040959 · 118 participants · Phase 2
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
- NCT04696029 · 118 participants · Phase 2
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
- NCT05223192 · 118 participants · NA
The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI